SSA
RUBY

Schonfeld Strategic Advisors’s Rubius Therapeutics, Inc RUBY Stock Holding History

Schonfeld Strategic Advisors’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-15,100
Closed -$6K – 3232
2022
Q3 		$6K Sell
15,100
-600
-4% -$450 ﹤0.01% 2748
2022
Q2 		$14K Buy
+15,700
New +$26.4K ﹤0.01% 2302
2021
Q3 		– Sell
-9,100
Closed -$222K – 2593
2021
Q2 		$222K Buy
+9,100
New +$228K ﹤0.01% 1621
2020
Q4 		– Sell
-20,300
Closed -$102K – 1968
2020
Q3 		$102K Buy
+20,300
New +$108K ﹤0.01% 1269

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Schonfeld Strategic Advisors's RUBY Position: Q4 2022 in Review

Schonfeld Strategic Advisors sold out of Rubius Therapeutics, Inc (RUBY) in Q4 2022, closing a stake of 15,100 shares — an estimated $6K sold.

Schonfeld Strategic Advisors first reported a position in RUBY in Q3 2020 and held it in 4 quarters. The position peaked at $222K in Q2 2021. 42 funds tracked by Wall St. Rank hold RUBY as of Q4 2022.

  • Schonfeld Strategic Advisors reported no remaining Rubius Therapeutics, Inc position as of Q4 2022 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 15,100 Rubius Therapeutics, Inc shares in Q4 2022, an estimated $6K.
  • Schonfeld Strategic Advisors first reported a position in Rubius Therapeutics, Inc in Q3 2020 and held it in 4 quarters.
  • Schonfeld Strategic Advisors's Rubius Therapeutics, Inc position peaked at $222K in Q2 2021.
  • 42 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q4 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.